216 related articles for article (PubMed ID: 33773592)
21. Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas.
Yue L; Wang T; Ge Y; Ge M; Zhang C; Hou Q; Wang W; Tian H; Ren B; Du B; Zhang W
Prostate; 2019 Feb; 79(3):312-319. PubMed ID: 30450670
[TBL] [Abstract][Full Text] [Related]
22. Circadian rhythm of blood pressure in patients with benign prostatic hyperplasia.
Turgut F; Bayrak O; Kanbay M; Ozkara A; Uz E; Bavbek N; Kargili A; Akcay A
Scand J Urol Nephrol; 2008; 42(1):47-52. PubMed ID: 17853012
[TBL] [Abstract][Full Text] [Related]
23. [Association between obesity-related plasma hemodilution and the concentration of prostate specific antigen].
Li F; Yin X; Li D; Yin Z; Qi S; Shi H; Gao J; Zhang X
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Dec; 35(12):1721-4. PubMed ID: 26714904
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
25. Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.
Schenk JM; Kristal AR; Arnold KB; Tangen CM; Neuhouser ML; Lin DW; White E; Thompson IM
Am J Epidemiol; 2011 Jun; 173(12):1419-28. PubMed ID: 21540324
[TBL] [Abstract][Full Text] [Related]
26. Risk behaviours and benign prostatic hyperplasia.
Kang D; Andriole GL; Van De Vooren RC; Crawford D; Chia D; Urban DA; Reding D; Huang WY; Hayes RB
BJU Int; 2004 Jun; 93(9):1241-5. PubMed ID: 15180615
[TBL] [Abstract][Full Text] [Related]
27. Central obesity as a risk factor for prostatic hyperplasia.
Lee S; Min HG; Choi SH; Kim YJ; Oh SW; Kim YJ; Park Y; Kim SS
Obesity (Silver Spring); 2006 Jan; 14(1):172-9. PubMed ID: 16493136
[TBL] [Abstract][Full Text] [Related]
28. Indications for and use of nonsteroidal antiinflammatory drugs and the risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Schenk JM; Calip GS; Tangen CM; Goodman P; Parsons JK; Thompson IM; Kristal AR
Am J Epidemiol; 2012 Jul; 176(2):156-63. PubMed ID: 22759721
[TBL] [Abstract][Full Text] [Related]
29. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men.
Meigs JB; Mohr B; Barry MJ; Collins MM; McKinlay JB
J Clin Epidemiol; 2001 Sep; 54(9):935-44. PubMed ID: 11520654
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
[TBL] [Abstract][Full Text] [Related]
31. Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.
Hammarsten J; Högstedt B
Eur Urol; 2001 Feb; 39(2):151-8. PubMed ID: 11223674
[TBL] [Abstract][Full Text] [Related]
32. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Hwang EC; Jung JH; Borofsky M; Kim MH; Dahm P
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD013143. PubMed ID: 30759311
[TBL] [Abstract][Full Text] [Related]
33. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
34. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.
Roehrborn CG; McConnell J; Bonilla J; Rosenblatt S; Hudson PB; Malek GH; Schellhammer PF; Bruskewitz R; Matsumoto AM; Harrison LH; Fuselier HA; Walsh P; Roy J; Andriole G; Resnick M; Waldstreicher J
J Urol; 2000 Jan; 163(1):13-20. PubMed ID: 10604304
[TBL] [Abstract][Full Text] [Related]
35. Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk.
Hung SC; Lai SW; Tsai PY; Chen PC; Wu HC; Lin WH; Sung FC
Br J Cancer; 2013 May; 108(9):1778-83. PubMed ID: 23612451
[TBL] [Abstract][Full Text] [Related]
36. Comparative analysis of resected prostate weight in diabetic and non-diabetic benign prostatic hyperplasia Patients.
Moudi E; Akbarzadeh-Pasha A
Caspian J Intern Med; 2017; 8(2):99-103. PubMed ID: 28702148
[TBL] [Abstract][Full Text] [Related]
37. Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.
Schenk JM; Kristal AR; Neuhouser ML; Tangen CM; White E; Lin DW; Thompson IM
Prostate; 2009 Sep; 69(12):1303-11. PubMed ID: 19475640
[TBL] [Abstract][Full Text] [Related]
38. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.
Pinsky PF; Kramer BS; Crawford ED; Grubb RL; Urban DA; Andriole GL; Chia D; Levin DL; Gohagan JK
Urology; 2006 Aug; 68(2):352-6. PubMed ID: 16904451
[TBL] [Abstract][Full Text] [Related]
39. Benign prostate hyperplasia: average volume in southwestern Nigerians and correlation with anthropometrics.
Badmus TA; Asaleye CM; Badmus SA; Takure AO; Ibrahim MH; Arowolo OA
Niger Postgrad Med J; 2012 Mar; 19(1):15-8. PubMed ID: 22430596
[TBL] [Abstract][Full Text] [Related]
40. Nocturia and benign prostatic hyperplasia.
Yoshimura K; Ohara H; Ichioka K; Terada N; Matsui Y; Terai A; Arai Y
Urology; 2003 Apr; 61(4):786-90. PubMed ID: 12670566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
